Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics-Reference-Cited by-同舟云学术

Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics

Published:2021-05-02 Issue:6 Volume:47 Page:736-747
ISSN:0305-1846
Container-title:Neuropathology and Applied Neurobiology
language:en
Short-container-title:Neuropathol Appl Neurobiol

Author:

Crosier Stephen¹²,Hicks Debbie¹,Schwalbe Edward C.¹³,Williamson Daniel¹,Leigh Nicholson Sarah²,Smith Amanda¹,Lindsey Janet C.¹,Michalski Antony⁴,Pizer Barry⁵,Bailey Simon¹,Bown Nick²,Cuthbert Gavin²,Wharton Stephen B.⁶^ORCID,Jacques Thomas S.⁷^ORCID,Joshi Abhijit²,Clifford Steven C.¹^ORCID

Affiliation:

1. Newcastle University Centre for Cancer Wolfson Childhood Cancer Research Centre Translational and Clinical Research Institute Faculty of Medical Sciences Newcastle University Newcastle upon Tyne UK

2. Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK

3. Department of Applied Sciences Northumbria University Newcastle UK

4. Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust London UK

5. Department of Haematology and Oncology Alder Hey Children's Hospital Liverpool UK

6. Sheffield Institute for Translational Neuroscience Sheffield University Sheffield UK

7. Developmental Biology & Cancer Department UCL GOS Institute of Child Health London UK

Funder

Great Ormond Street Hospital Charity

Brain Tumour Charity

CHILDREN with CANCER UK

National Institute for Health Research

Cancer Research UK

Publisher

Wiley

Subject

Physiology (medical),Neurology (clinical),Neurology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nan.12716

Reference26 articles.

1. Rare cancers are not so rare: The rare cancer burden in Europe

2. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

3. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study

4. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies

5. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups;eBioMedicine;2024-02

2. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification;Acta Neuropathologica;2023-04-04

3. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts;Acta Neuropathologica;2022-12-02

4. How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?;JCO Global Oncology;2022-12

5. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas;Acta Neuropathologica;2022-10-01